Indian pharmaceutical companies seeking to register products in Congo DR must navigate a structured process overseen by the Congolese Pharmaceutical Regulatory Authority (ACOREP). The registration requires submission of a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy.
While Good Manufacturing Practice (GMP) certification is officially mandated, enforcement can be inconsistent. A Certificate of Pharmaceutical Product (CPP) is a critical document in the registration process. Quality control measures include initial screening using methods like the GPHF Minilab, with more comprehensive analysis performed at WHO-prequalified laboratories abroad.
The entire process, from clinical trial application to market entry, is managed by ACOREP, which aims to provide a decision on clinical trial applications within 30 days of submission, following ethics committee approval. Failure to meet regulations, including the mandatory use of French on all documentation and labeling, can lead to significant sanctions, mirroring global standards that include product recalls and fines.
